Back to top
more

Omeros (OMER)

(Delayed Data from NSDQ)

$3.15 USD

3.15
172,888

+0.09 (2.94%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.14 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Brian Bolan headshot

Brian's Big Idea on Biotech

by Brian Bolan

A look at drugs for drug addiction and the biotech space.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day.

Indrajit Bandyopadhyay headshot

3 Medical Stocks Creating Wealth Despite Macro Challenges

by Indrajit Bandyopadhyay

Here we discuss three stocks - LNTH, OMER and HYPR - that have been creating wealth for their investors in 2023 even though several competitors faltered amid macro challenges. Will the trend continue?

Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 126.2% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Earnings Season Could Be Great for Omeros (OMER)

by Zacks Equity Research

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Do Options Traders Know Something About Omeros (OMER) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 42.22% and 2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 59.6% in 4 Weeks, Here's Why Omeros (OMER) Looks Ripe for a Turnaround

by Zacks Equity Research

Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Omeros (OMER) Soars 9.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Omeros (OMER) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Do Options Traders Know Something About Omeros (OMER) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

by Zacks Equity Research

Omeros (OMER) announces initial results from a phase I study of OMS906.

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

by Zacks Equity Research

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients

by Zacks Equity Research

Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.

Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.

Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

by Zacks Equity Research

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) in Focus: Stock Moves 8.5% Higher

by Zacks Equity Research

Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?